Related Articles
Assessment of frequency and severity of hypomagnesemia in patients with metastatic colorectal cancer treated with cetuximab, with a review of the literature
Incidence and risk of hypomagnesemia in advanced cancer patients treated with cetuximab: A meta‑analysis
Research progress on common adverse events caused by targeted therapy for colorectal cancer (Review)
Efficacy of combination chemotherapy using a novel oral chemotherapeutic agent, TAS-102, together with bevacizumab, cetuximab, or panitumumab on human colorectal cancer xenografts
Impact of EGFR and EGFR ligand expression on treatment response in patients with metastatic colorectal cancer